Menu
Using our Symphony™ platform, Aria has developed a pipeline of promising treatments in over a dozen programs across a range of therapeutic areas. All our candidates have novel mechanisms of action that have shown statistically significant efficacy in preclinical studies. But that’s just the beginning. We have the power to apply our science in 1000+ complex diseases.
Symphony™ is Aria’s proprietary drug-discovery AI-platform that decodes complex biology problems to find novel ways of targeting challenging diseases with greater speed and a higher rate of certainty than traditional drug discovery processes.
Symphony™ is Aria’s proprietary drug-discovery AI-platform that decodes complex biology problems to find novel ways of targeting challenging diseases with greater speed and a higher rate of certainty than traditional drug discovery processes.
Leveraging Artificial Intelligence to Identify Drug Leads & Establish Safety & Efficacy from Human Derived Data
Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty
Leveraging AI From Human Derived Data to Identify Drug Leads and Establish Efficacy for IPF and NASH
Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty
Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF
Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF
Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF
Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty
Discovery & Preclinical Validation of Two Therapeutic Leads with Novel MOAs for IPF
Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD
Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD
Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)
Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer
Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)
Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma
Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma
Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)
Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)
Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)
Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)
Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer